Astrocytes in Parkinson's disease: Beyond support, toward therapy.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and theoretical therapeutic models without new clinical data.
PubMed 42586469 · doi:10.1016/j.expneurol.2026.115964
What was done
This is a narrative review synthesizing literature on the mechanistic and therapeutic roles of astrocytes in Parkinson's disease pathogenesis and therapy. It examines mechanisms including astrocyte-to-neuron reprogramming, A2 phenotypic polarization, oxidative stress suppression, metal ion deposition modulation, neurotransmitter homeostasis, alpha-synuclein clearance, and delivery platforms such as gene therapy, nanoparticles, and astrocyte-derived exosomes.
What was found
The abstract reports no numerical data or quantitative outcomes. It describes qualitatively that astrocytes exert dual protective and pathogenic roles in Parkinson's disease progression and argues for a paradigm shift toward a glia-inclusive therapeutic framework.
Why it matters
It consolidates mechanistic rationale for shifting Parkinson's disease therapeutics beyond direct neuronal targets toward glial-directed neuroprotection and cell-reprogramming strategies.
Limits
As a narrative review, the paper presents no original clinical or experimental data, and the abstract includes no sample sizes or systematic search parameters. Therapeutic strategies discussed are preclinical and theoretical rather than clinically validated treatments.
Cited by
- supports In Parkinson's disease, dopaminergic neurons in the substantia nigra of the midbrain die.